These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 8519676)
1. Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study. Betticher DC; Anderson H; Ranson M; Meely K; Oster W; Thatcher N Br J Cancer; 1995 Dec; 72(6):1551-5. PubMed ID: 8519676 [TBL] [Abstract][Full Text] [Related]
2. Amifostine reduces radiochemotherapy-induced toxicities in patients with locally advanced non-small cell lung cancer. Antonadou D; Petridis A; Synodinou M; Throuvalas N; Bolanos N; Veslemes M; Sagriotis A Semin Oncol; 2003 Dec; 30(6 Suppl 18):2-9. PubMed ID: 14727235 [TBL] [Abstract][Full Text] [Related]
3. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Komaki R; Lee JS; Milas L; Lee HK; Fossella FV; Herbst RS; Allen PK; Liao Z; Stevens CW; Lu C; Zinner RG; Papadimitrakopoulou VA; Kies MS; Blumenschein GR; Pisters KM; Glisson BS; Kurie J; Kaplan B; Garza VP; Mooring D; Tucker SL; Cox JD Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1369-77. PubMed ID: 15050312 [TBL] [Abstract][Full Text] [Related]
4. Carboplatin and paclitaxel in non-small cell lung cancer: the role of amifostine. Selvaggi G; Belani CP Semin Oncol; 1999 Apr; 26(2 Suppl 7):51-60. PubMed ID: 10348261 [TBL] [Abstract][Full Text] [Related]
5. Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer. Antonadou D; Throuvalas N; Petridis A; Bolanos N; Sagriotis A; Synodinou M Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):402-8. PubMed ID: 12957251 [TBL] [Abstract][Full Text] [Related]
6. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. Movsas B; Scott C; Langer C; Werner-Wasik M; Nicolaou N; Komaki R; Machtay M; Smith C; Axelrod R; Sarna L; Wasserman T; Byhardt R J Clin Oncol; 2005 Apr; 23(10):2145-54. PubMed ID: 15800308 [TBL] [Abstract][Full Text] [Related]
7. Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results. Komaki R; Lee JS; Kaplan B; Allen P; Kelly JF; Liao Z; Stevens CW; Fossella FV; Zinner R; Papadimitrakopoulou V; Khuri F; Glisson B; Pisters K; Kurie J; Herbst R; Milas L; Ro J; Thames HD; Hong WK; Cox JD Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):46-9. PubMed ID: 11917284 [TBL] [Abstract][Full Text] [Related]
8. Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors. Budd GT; Ganapathi R; Adelstein DJ; Pelley R; Olencki T; Petrus J; McLain D; Zhang J; Capizzi R; Bukowski RM Cancer; 1997 Sep; 80(6):1134-40. PubMed ID: 9305715 [TBL] [Abstract][Full Text] [Related]
9. Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Büntzel J; Glatzel M; Kuttner K; Weinaug R; Fröhlich D Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):4-13. PubMed ID: 11917277 [TBL] [Abstract][Full Text] [Related]
10. Administration of Ethyol (amifostine) to a child with medulloblastoma to ameliorate hematological toxicity of high dose carboplatin. Borsi JD; Csaki C; Ferencz T; Oster W Anticancer Drugs; 1996 Jan; 7(1):121-6. PubMed ID: 8742109 [TBL] [Abstract][Full Text] [Related]
11. Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. Bennett CL; Lane D; Stinson T; Glatzel M; Buntzel J Cancer Invest; 2001; 19(2):107-13. PubMed ID: 11296615 [TBL] [Abstract][Full Text] [Related]
12. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. Leong SS; Tan EH; Fong KW; Wilder-Smith E; Ong YK; Tai BC; Chew L; Lim SH; Wee J; Lee KM; Foo KF; Ang P; Ang PT J Clin Oncol; 2003 May; 21(9):1767-74. PubMed ID: 12721253 [TBL] [Abstract][Full Text] [Related]
13. A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation. Hartmann JT; von Vangerow A; Fels LM; Knop S; Stolte H; Kanz L; Bokemeyer C Br J Cancer; 2001 Feb; 84(3):313-20. PubMed ID: 11161394 [TBL] [Abstract][Full Text] [Related]
14. The potential of amifostine: from cytoprotectant to therapeutic agent. Santini V; Giles FJ Haematologica; 1999 Nov; 84(11):1035-42. PubMed ID: 10553165 [TBL] [Abstract][Full Text] [Related]
16. Protective effect of amifostine against toxicity of paclitaxel and carboplatin in non-small cell lung cancer: a single center randomized study. Kanat O; Evrensel T; Baran I; Coskun H; Zarifoglu M; Turan OF; Kurt E; Demiray M; Gonullu G; Manavoglu O Med Oncol; 2003; 20(3):237-45. PubMed ID: 14514973 [TBL] [Abstract][Full Text] [Related]
17. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results. Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671 [TBL] [Abstract][Full Text] [Related]
18. Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano. Comella P; Frasci G; De Cataldis G; Panza N; Cioffi R; Curcio C; Belli M; Bianco A; Ianniello G; Maiorino L; Della Vittoria M; Perchard J; Comella G Br J Cancer; 1996 Dec; 74(11):1805-11. PubMed ID: 8956797 [TBL] [Abstract][Full Text] [Related]
19. Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Lorusso D; Ferrandina G; Greggi S; Gadducci A; Pignata S; Tateo S; Biamonte R; Manzione L; Di Vagno G; Ferrau' F; Scambia G; Ann Oncol; 2003 Jul; 14(7):1086-93. PubMed ID: 12853351 [TBL] [Abstract][Full Text] [Related]
20. Randomized phase II study of amifostine mucosal protection by either subcutaneous injection or rapid IV bolus for patients with inoperable stage II-IIIA/B or stage IV non-small cell lung cancer with oligometastases receiving concurrent radiochemotherapy with carboplatin and paclitaxel followed by optional consolidative chemotherapy: a follow-up study after RTOG 98-01. Werner-Wasik M; Langer C; Movsas B Semin Oncol; 2004 Dec; 31(6 Suppl 18):47-51. PubMed ID: 15726523 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]